10.4 Antifungal drugs
4 min read•august 16, 2024
Antifungal drugs are crucial weapons against fungal infections. They work in different ways to kill fungi or stop their growth. From polyenes that punch holes in fungal cells to that mess with their membranes, these drugs have various tricks up their sleeves.
Getting antifungal drugs into the body and to the right spots can be tricky. Some are easy to swallow, while others need to be injected. Once inside, they spread around, get broken down, and leave the body in different ways. Knowing how they move and change helps doctors use them safely and effectively.
Antifungal Drug Classification
Mechanism of Action and Drug Classes
Top images from around the web for Mechanism of Action and Drug Classes
Frontiers | Antifungal Therapy: New Advances in the Understanding and Treatment of Mycosis ... View original
Is this image relevant?
Frontiers | Membrane-Interacting Antifungal Peptides View original
Is this image relevant?
Frontiers | Fungal Cell Wall: Emerging Antifungals and Drug Resistance View original
Is this image relevant?
Frontiers | Antifungal Therapy: New Advances in the Understanding and Treatment of Mycosis ... View original
Is this image relevant?
Frontiers | Membrane-Interacting Antifungal Peptides View original
Is this image relevant?
1 of 3
Top images from around the web for Mechanism of Action and Drug Classes
Frontiers | Antifungal Therapy: New Advances in the Understanding and Treatment of Mycosis ... View original
Is this image relevant?
Frontiers | Membrane-Interacting Antifungal Peptides View original
Is this image relevant?
Frontiers | Fungal Cell Wall: Emerging Antifungals and Drug Resistance View original
Is this image relevant?
Frontiers | Antifungal Therapy: New Advances in the Understanding and Treatment of Mycosis ... View original
Is this image relevant?
Frontiers | Membrane-Interacting Antifungal Peptides View original
Is this image relevant?
1 of 3
- Antifungal drugs categorized into four main classes based on distinct mechanisms of action
- Polyenes bind to ergosterol in fungal cell membranes creating pores leading to cell death
- Azoles inhibit ergosterol synthesis by blocking lanosterol 14α-demethylase enzyme
- inhibit β-1,3-D-glucan synthesis a key fungal cell wall component
- have unique mechanisms ( interferes with DNA/RNA synthesis, disrupts microtubule function)
Spectrum of Activity
- Polyenes demonstrate broad spectrum activity against many fungi (Candida, Aspergillus)
- Azoles effective against wide range of yeasts and molds with varying spectra within class
- Echinocandins primarily active against Candida species and some Aspergillus species
- Spectrum varies from broad-spectrum (effective against many fungi) to narrow-spectrum (targeting specific fungi)
- Examples of broad-spectrum antifungals include and
- Examples of narrow-spectrum antifungals include griseofulvin () and flucytosine (Candida, )
Pharmacokinetics of Antifungal Agents
Absorption and Distribution
- Oral absorption varies among antifungal agents
- Azoles generally have good oral (fluconazole >90%, itraconazole 55%)
- Echinocandins and amphotericin B require administration due to poor oral absorption
- Distribution influenced by lipophilicity and protein binding
- Lipophilic agents (voriconazole, posaconazole) achieve high tissue concentrations including central nervous system
- Protein binding affects free drug concentration (fluconazole 11-12%, voriconazole 58%, caspofungin 97%)
Metabolism and Excretion
- Azoles primarily metabolized in liver via cytochrome P450 enzymes
- Potential for drug interactions due to enzyme inhibition or induction
- Examples: fluconazole inhibits CYP2C9, voriconazole inhibits CYP3A4
- Echinocandins undergo minimal hepatic metabolism
- Caspofungin partially metabolized, micafungin and anidulafungin not significantly metabolized
- Amphotericin B not significantly metabolized in the body
- Excretion routes differ among antifungal classes
- Azoles eliminated through hepatic metabolism and renal excretion
- Echinocandins excreted unchanged in feces and urine
- Amphotericin B primarily eliminated through slow hepatic metabolism and biliary excretion
Routes of Administration
- Multiple routes available depending on drug and infection type
- Oral administration common for azoles (fluconazole, itraconazole)
- Intravenous route used for severe infections or poorly absorbed drugs (amphotericin B, echinocandins)
- preparations for superficial fungal infections (clotrimazole, miconazole)
- Inhalation route for prophylaxis or treatment of pulmonary infections (amphotericin B)
Antifungal Drug Indications and Risks
Indications and Contraindications
- Indications for antifungal drugs include systemic infections, superficial mycoses, and prophylaxis
- Systemic infections (invasive , )
- Superficial infections (oral thrush, dermatophytosis)
- Prophylaxis in high-risk patients (neutropenic, transplant recipients)
- Contraindications vary based on drug class and individual agents
- Hypersensitivity to drug class (azole allergy, echinocandin hypersensitivity)
- Severe hepatic impairment for certain azoles (voriconazole, posaconazole)
- Pregnancy for some agents (category C or D drugs like itraconazole, posaconazole)
- Specific contraindications (voriconazole in long QT syndrome, amphotericin B in severe renal impairment)
Adverse Effects and Monitoring
- Azoles associated with , gastrointestinal disturbances, and drug interactions
- Liver function test monitoring required (ALT, AST, alkaline phosphatase)
- Common GI effects include nausea, vomiting, diarrhea
- Drug interactions due to CYP450 enzyme inhibition (warfarin, tacrolimus)
- Amphotericin B linked to significant nephrotoxicity and infusion-related reactions
- Renal function monitoring (, BUN, electrolytes)
- Infusion reactions (fever, chills, hypotension) managed with premedication
- Lipid formulations (liposomal amphotericin B) have improved safety profiles
- Echinocandins generally well-tolerated with mild adverse effects
- Fever, nausea, elevated liver enzymes reported
- Fewer drug interactions compared to azoles
- Rare but serious adverse effects require immediate drug discontinuation
- Stevens-Johnson syndrome with certain azoles (voriconazole)
- Anaphylaxis possible with any antifungal agent
- Torsades de pointes with QT-prolonging azoles (voriconazole)
Prophylactic Antifungal Therapy
Patient Selection and Drug Choice
- Prophylactic therapy prevents fungal infections in high-risk, immunocompromised patients
- Hematopoietic stem cell transplant recipients
- Patients receiving chemotherapy for hematologic malignancies
- Solid organ transplant recipients
- Choice of prophylactic agent based on patient risk factors, immunosuppression duration, and local epidemiology
- Fluconazole commonly used for Candida prophylaxis
- Posaconazole preferred for patients at risk for mold infections (acute myeloid leukemia)
- Risk stratification crucial in determining prophylaxis need
- Factors include immunosuppression type and duration, neutropenia severity, graft-versus-host disease presence
Duration and Monitoring
- Prophylaxis duration varies based on underlying condition and risk factors
- Short-term (weeks) for neutropenic patients undergoing chemotherapy
- Long-term (months) for stem cell transplant recipients with chronic GVHD
- Monitoring for breakthrough fungal infections essential
- Clinical surveillance for signs and symptoms of infection
- Periodic fungal biomarker testing (galactomannan, beta-D-glucan)
- Adjusting prophylactic regimens based on local resistance patterns and patient-specific factors
- Switching to broader spectrum agents if breakthrough infections occur
- Dose adjustments for patients with organ dysfunction or drug interactions
Considerations and Challenges
- Potential drawbacks of prophylactic therapy include:
- Development of antifungal resistance (emergence of azole-resistant Candida species)
- Drug toxicity (hepatotoxicity with prolonged azole use)
- Increased healthcare costs (high cost of newer antifungal agents)
- Benefits must be weighed against risks for each patient
- Individualized approach considering patient comorbidities and risk factors
- Regular reassessment of need for continued prophylaxis
- Emerging strategies to optimize prophylaxis
- Risk-adapted approaches tailoring prophylaxis to patient-specific factors
- Combination strategies using different drug classes for high-risk patients
- Integration of antifungal stewardship programs to guide appropriate use
Key Terms to Review (24)
Amphotericin b: Amphotericin B is an antifungal medication primarily used to treat serious fungal infections by targeting the cell membranes of fungi. It is often considered the gold standard for treating invasive fungal infections due to its broad spectrum of activity against many pathogenic fungi, including species that cause systemic mycoses. Understanding how amphotericin B works and its clinical applications is crucial in managing severe fungal infections effectively.
Aspergillosis: Aspergillosis is a fungal infection caused by the Aspergillus species, primarily affecting the respiratory system, but can also impact other organs. It often occurs in individuals with weakened immune systems or those with underlying lung conditions, leading to serious health complications. Understanding this condition is crucial in the context of antifungal treatments, as these medications are essential for managing and treating infections effectively.
Azoles: Azoles are a class of antifungal agents that inhibit the synthesis of ergosterol, an essential component of fungal cell membranes. By disrupting ergosterol production, azoles compromise the integrity of the fungal cell membrane, leading to cell death. This class includes both imidazoles and triazoles, which differ in their chemical structure and spectrum of activity against various fungal pathogens.
Bioavailability: Bioavailability refers to the proportion of a drug that enters the systemic circulation when introduced into the body and is available for therapeutic effect. It is influenced by factors such as the route of administration, formulation of the drug, and individual patient characteristics, making it a crucial aspect of pharmacology, drug development, and therapeutic effectiveness.
Candidiasis: Candidiasis is a fungal infection caused by Candida species, most commonly Candida albicans. It can manifest in various forms, including oral thrush, vaginal yeast infections, and systemic infections, particularly in immunocompromised individuals. Understanding candidiasis is crucial when studying antifungal drugs, as effective treatments are necessary to manage these infections and prevent complications.
CDC Recommendations: CDC recommendations refer to the guidelines and protocols established by the Centers for Disease Control and Prevention to inform healthcare professionals and the public about the prevention, diagnosis, and treatment of various diseases, including fungal infections. These recommendations are based on the latest scientific evidence and aim to reduce the risk of infections and improve patient outcomes in diverse healthcare settings.
Cell wall synthesis inhibition: Cell wall synthesis inhibition refers to the mechanism by which certain antifungal drugs disrupt the formation of the fungal cell wall, an essential structure for maintaining the integrity and shape of the organism. This process is crucial in treating fungal infections, as it selectively targets the unique components of fungal cell walls, such as chitin and glucan, leading to cell lysis and ultimately, the death of the fungus. Understanding this mechanism highlights the importance of antifungal therapies in combating various fungal pathogens.
Cryptococcus: Cryptococcus is a genus of fungi known for its spherical yeast-like cells and prominent polysaccharide capsule. This organism is particularly significant in medicine due to its role as an opportunistic pathogen, especially in immunocompromised individuals, leading to conditions such as cryptococcosis, which often affects the lungs and central nervous system. Understanding cryptococcus is essential in the context of antifungal treatments, as specific drugs are required to combat infections caused by this fungus.
Dermatophytes: Dermatophytes are a group of fungi that cause superficial infections of the skin, hair, and nails, commonly referred to as dermatophytoses or ringworm. These fungi thrive in keratin-rich environments, utilizing keratin as their primary source of nutrition. They can infect various parts of the body, leading to symptoms such as itching, redness, and scaling, making them significant in the study of antifungal therapies.
Echinocandins: Echinocandins are a class of antifungal agents that inhibit the synthesis of β-(1,3)-D-glucan, an essential component of fungal cell walls. This action makes them effective against various types of fungi, particularly Candida and Aspergillus species, which can cause serious infections in immunocompromised patients. Echinocandins are typically administered intravenously and have a favorable safety profile compared to other antifungals.
Ergosterol synthesis inhibition: Ergosterol synthesis inhibition refers to the mechanism by which certain antifungal drugs disrupt the production of ergosterol, a crucial component of fungal cell membranes. By targeting enzymes involved in the biosynthesis of ergosterol, these drugs compromise the integrity of the fungal membrane, leading to cell lysis and ultimately the death of the fungal organism. This selective toxicity is essential for effectively treating fungal infections without harming human cells, which use cholesterol instead of ergosterol.
Flucytosine: Flucytosine is an antifungal medication that is primarily used to treat systemic fungal infections, especially those caused by Candida and Cryptococcus species. It works by inhibiting fungal DNA synthesis, thereby preventing the growth and replication of fungal cells. Often used in combination with other antifungal agents, flucytosine enhances treatment effectiveness and helps combat resistance.
Griseofulvin: Griseofulvin is an antifungal medication used primarily to treat skin and nail infections caused by dermatophytes. It works by inhibiting fungal cell division and disrupting the mitotic spindle, which helps to prevent the spread of the infection within the body. This drug is particularly effective against conditions like tinea capitis (scalp ringworm) and onychomycosis (nail fungus).
Half-life: Half-life is the time it takes for the concentration of a drug in the bloodstream to reduce to half of its initial value. This concept is essential for understanding how drugs are metabolized and eliminated from the body, influencing dosing regimens and therapeutic outcomes.
Hepatotoxicity: Hepatotoxicity refers to the capacity of certain substances, such as drugs and chemicals, to cause damage to the liver. This condition can arise from various medications and substances that lead to liver injury through direct cellular toxicity or immune-mediated mechanisms, resulting in adverse effects on liver function.
IDSA Guidelines: The IDSA Guidelines refer to the evidence-based recommendations developed by the Infectious Diseases Society of America for the diagnosis and treatment of various infectious diseases, including those caused by fungi. These guidelines provide clinicians with a framework to optimize patient care by addressing best practices in antifungal therapy, considering factors like efficacy, safety, and resistance patterns.
Intravenous: Intravenous refers to the administration of substances directly into a vein, allowing for rapid delivery of medications and fluids into the bloodstream. This method is often used in various medical settings for its ability to provide immediate effects, making it ideal for emergencies, surgical procedures, and certain therapeutic treatments.
Liver function tests: Liver function tests (LFTs) are a series of blood tests used to assess the health and functionality of the liver by measuring the levels of various enzymes, proteins, and substances produced or processed by the liver. These tests help detect liver diseases, monitor liver health during treatments, and evaluate the effects of medications. Understanding LFTs is crucial in managing pharmacotherapy, especially for drugs that can affect liver health, as they inform dosage adjustments and identify potential drug-induced liver injury.
Miscellaneous agents: Miscellaneous agents refer to a diverse group of antifungal drugs that do not fit neatly into the major categories of antifungal treatments, such as azoles or polyenes. These agents often have unique mechanisms of action or are used for specific types of fungal infections that are not covered by traditional antifungal therapies. Understanding these agents is crucial for effectively treating a broad range of fungal infections, particularly those that may be resistant to standard treatments.
Polyene: Polyenes are a class of antifungal agents characterized by their multiple conjugated double bonds, which play a crucial role in their mechanism of action. These compounds primarily target fungal cell membranes by binding to ergosterol, a key component in fungal cells, leading to increased membrane permeability and cell death. Their effectiveness makes them a cornerstone in the treatment of various fungal infections, particularly those caused by systemic fungi.
QT interval prolongation: QT interval prolongation refers to an extended duration of the QT interval on an electrocardiogram (ECG), which represents the time it takes for the heart's electrical system to reset after each heartbeat. This condition can lead to serious heart rhythm disorders, increasing the risk of life-threatening arrhythmias like Torsades de Pointes. Certain antibacterial and antifungal agents can impact cardiac repolarization, contributing to this prolonged QT interval.
Serum creatinine: Serum creatinine is a waste product formed from the normal breakdown of muscle tissue, which is then filtered out of the blood by the kidneys. Elevated levels of serum creatinine can indicate impaired kidney function, making it an important biomarker in assessing renal health, especially when considering the use of antifungal drugs that may affect renal function.
Topical: Topical refers to a method of delivering medication directly to a specific area of the body, usually through the skin or mucous membranes. This route allows for localized treatment while minimizing systemic absorption and side effects, making it especially useful for conditions affecting the skin or mucosal surfaces.
Voriconazole: Voriconazole is an antifungal medication used primarily to treat serious fungal infections, particularly those caused by Aspergillus species and Candida. It works by inhibiting the synthesis of ergosterol, an essential component of fungal cell membranes, which ultimately leads to cell death. This drug is vital for managing invasive fungal infections, especially in immunocompromised patients.